Last reviewed · How we verify
NCT07112989: PREMOD
Development of Innovative Preclinical Ex Vivo Models for the Study of Sarcomas and Metastases From Solid Tumors
trial in Bone and Soft Tissue Tumors in 125 participants. Currently enrolling.
23 September 2031
Quick facts
| Lead sponsor | Istituto Ortopedico Rizzoli |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 125 |
| Start date | 23 September 2024 |
| Primary completion | 23 September 2031 |
| Estimated completion | 23 September 2031 |
| Sites | 1 location across Italy |
Conditions studied
- Bone and Soft Tissue Tumors — all drugs for Bone and Soft Tissue Tumors →
- Bone Metastases From Solid Tumors — all drugs for Bone Metastases From Solid Tumors →
- Lung Metastases — all drugs for Lung Metastases →
Sponsor
Istituto Ortopedico Rizzoli — full company profile →
Who can join
Under 85, any sex, with Bone and Soft Tissue Tumors or Bone Metastases From Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to learn how tumor tissue and blood samples from patients with sarcomas or metastases can be used to create laboratory models that help researchers study cancer behavior and test new treatments. Participants diagnosed with sarcoma or with bone or lung metastases from solid tumors will donate leftover tumor tissue and blood collected during their regular medical care. These samples will be used in the lab to build 3D models of the tumor, test drugs, and identify genetic and molecular markers. No treatments or procedures will be given as part of the study.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07112989
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bone and Soft Tissue Tumors
Currently open trials in the same condition.
- NCT06939855 — QL1706 in the Treatment of Advanced Bone and Soft Tissue Sarcoma · Phase 2 · recruiting
- NCT06599957 — Innovative Drug Delivery Nanophotonic Platform for Implementation of Sarcoma Therapy · recruiting
- NCT05468970 — Study on Clinical Features, Treatment Mode and Survival of Bone and Soft Tissue Tumors · recruiting
Other Istituto Ortopedico Rizzoli trials
Trials by the same sponsor.
- NCT07590882 — Evaluation of Return to Sports Activity After Periacetabular Osteotomy: An Observational Study · enrolling by invitation
- NCT07021222 — Multifactorial Strategies for the Prevention of the Risks of Ulceration in Patients Affected by Diabetic Foot (DARE-DiaF · NA · recruiting
- NCT07360964 — Clear Cell Chondrosarcoma in Italy · NA · active not recruiting
- NCT07140367 — "Transarterial Microembolization (TAME) in Inflammatory Knee Pathology" · recruiting
- NCT07102875 — Ready to Sail 2: A Pilot Study of Sail-Assisted Telerehabilitation in Rare Skeletal Diseases · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07112989 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Istituto Ortopedico Rizzoli
- Last refreshed: 8 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07112989.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing